

Date: 29.09.2026

To,
Listing Department
National Stock Exchange of India Limited
("NSE")
Exchange Plaza, C-1 Block G, Bandra Kurla
Complex Bandra [E], Mumbai – 400051
NSE Scrip Symbol: PLATIND
ISIN: INEOPT501018

To,
Listing Department
BSE Limited ("BSE")
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai - 400 001
BSE Scrip Code: 544134
ISIN: INEOPT501018

Subject: Intimation regarding Exclusive Sale/Purchase Agreement entered into by our Subsidiary – Rivadu Lifesciences Private Limited

Dear Sir / Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that **Rivadu Lifesciences Private Limited ("Rivadu")**, a subsidiary of Platinum Industries Limited, has entered into an **exclusive Sale/Purchase Agreement** for India on 28th September 2026, with **CAREGEN Co., Ltd., Korea ("CAREGEN")** in relation to Caregen's health functional food finished products marketed under the brand name **"Korglutide"**.

The relevant details as required under Regulation 30 read with Schedule III of the SEBI Listing Regulations are enclosed as **Annexure A**.

The above information shall be made available on the website of the Company at www.platinumindustriesltd.com.

Kindly take the above intimation on your record and oblige.

Thanking You,

Yours Faithfully,

For Platinum Industries Limited

BHAGYASHREE
E MALLAWAT
Digitally signed by
BHAGYASHREE
MALLAWAT
Date: 2026.09.29
11:17:43 +05'30'

Bhagyashree Mallawat
Company Secretary and Compliance Officer
M. No.: A51488



Disclosure of information pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, read with Circular SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Sr. No.	Particular	Details
	Name of the entity entering into the agreement	Rivadu Lifesciences Private Limited, Subsidiary of Platinum Industries Limited
1	Name of the entity with whom agreement is entered	CAREGEN Co., Ltd., Korea
2	Purpose of entering into the agreement	Exclusive Sale/Purchase Agreement for India in relation to Korglutide.
3	shareholding, if any, in the entity with whom the agreement is executed;	NA
4	significant terms of the agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc.;	- Exclusive Partnership for Indian Territory. - Prospects for establishing manufacturing in India.
5	whether, the said parties are related to promoter/promoter group/ group companies in any manner. If yes, nature of relationship	No, the entity with whom Agreement is executed is not related.
6	whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length"	No
7	in case of issuance of shares to the parties, details of issue price, class of shares issued;	NA
8	any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc.;	NA
9	In case of termination or amendment of agreement, listed entity shall disclose additional details to the stock exchange(s): a) name of parties to the agreement; b) nature of the agreement; c) date of execution of the agreement; d) details of amendment and impact thereof or reasons of termination and impact thereof.	NA